These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 28377723)

  • 1. Multiple Psychopharmacological Effects of the Traditional Japanese Kampo Medicine Yokukansan, and the Brain Regions it Affects.
    Mizoguchi K; Ikarashi Y
    Front Pharmacol; 2017; 8():149. PubMed ID: 28377723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropharmacological efficacy of the traditional Japanese Kampo medicine yokukansan and its active ingredients.
    Ikarashi Y; Mizoguchi K
    Pharmacol Ther; 2016 Oct; 166():84-95. PubMed ID: 27373856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular Pharmacological Effects of the Traditional Japanese Kampo Medicine Yokukansan on Brain Cells.
    Mizoguchi K; Ikarashi Y
    Front Pharmacol; 2017; 8():655. PubMed ID: 28979206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic Study of Drug-Drug Interaction between Memantine and the Traditional Japanese Kampo Medicine Yokukansan.
    Matsumoto T; Sekiguchi K; Kawakami Z; Watanabe J; Mizoguchi K; Ikarashi Y; Yamamoto M
    Molecules; 2018 Dec; 24(1):. PubMed ID: 30597998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Active Components of Yokukansan, a Traditional Japanese Herbal Medicine after a Single Oral Administration to Healthy Japanese Volunteers: A Cross-Over, Randomized Study.
    Kitagawa H; Munekage M; Ichikawa K; Fukudome I; Munekage E; Takezaki Y; Matsumoto T; Igarashi Y; Hanyu H; Hanazaki K
    PLoS One; 2015; 10(7):e0131165. PubMed ID: 26151135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Application of Yokukansan as a Remedy for Parkinson's Disease.
    Jang JH; Jung K; Kim JS; Jung I; Yoo H; Moon C
    Evid Based Complement Alternat Med; 2018; 2018():1875928. PubMed ID: 30671124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yokukansan and Yokukansankachimpihange Ameliorate Aggressive Behaviors in Rats with Cholinergic Degeneration in the Nucleus Basalis of Meynert.
    Tabuchi M; Mizuno K; Mizoguchi K; Hattori T; Kase Y
    Front Pharmacol; 2017; 8():235. PubMed ID: 28491038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of the benzodiazepine system in the anxiolytic-like effect of Yokukansan (Yi-gan san).
    Kamei J; Miyata S; Ohsawa M
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1431-7. PubMed ID: 19647028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder.
    Wake R; Miyaoka T; Furuya M; Hashioka S; Horiguchi J
    CNS Neurol Disord Drug Targets; 2016; 15(5):551-63. PubMed ID: 27071791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kampo formulations, chotosan, and yokukansan, for dementia therapy: existing clinical and preclinical evidence.
    Matsumoto K; Zhao Q; Niu Y; Fujiwara H; Tanaka K; Sasaki-Hamada S; Oka J
    J Pharmacol Sci; 2013; 122(4):257-69. PubMed ID: 23883485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine.
    Iwasaki K; Kosaka K; Mori H; Okitsu R; Furukawa K; Manabe Y; Yoshita M; Kanamori A; Ito N; Wada K; Kitayama M; Horiguchi J; Yamaguchi S; Takayama S; Fukuhara R; Ouma S; Nakano S; Hashimoto M; Kinoshita T
    Psychogeriatrics; 2012 Dec; 12(4):235-41. PubMed ID: 23279145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Geissoschizine methyl ether, an alkaloid in Uncaria hook, is a potent serotonin ₁A receptor agonist and candidate for amelioration of aggressiveness and sociality by yokukansan.
    Nishi A; Yamaguchi T; Sekiguchi K; Imamura S; Tabuchi M; Kanno H; Nakai Y; Hashimoto K; Ikarashi Y; Kase Y
    Neuroscience; 2012 Apr; 207():124-36. PubMed ID: 22314317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LC-MS/MS detection of citrus unshiu peel-derived flavonoids in the plasma and brain after oral administration of yokukansankachimpihange in rats.
    Takiyama M; Matsumoto T; Watanabe J
    Xenobiotica; 2019 Dec; 49(12):1494-1503. PubMed ID: 30741064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yokukansan inhibits social isolation-induced aggression and methamphetamine-induced hyperlocomotion in rodents.
    Uchida N; Egashira N; Iwasaki K; Ishibashi A; Tashiro R; Nogami A; Manome N; Abe M; Takasaki K; Mishima K; Takata J; Oishi R; Nishimura R; Fujiwara M
    Biol Pharm Bull; 2009 Mar; 32(3):372-5. PubMed ID: 19252280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Effects of Yokukansan and Yokukansankachimpihange on Glutamate Uptake by Cultured Astrocytes and Glutamate-Induced Excitotoxicity in Cultured PC12 Cells.
    Kawakami Z; Omiya Y; Mizoguchi K
    Evid Based Complement Alternat Med; 2019; 2019():9139536. PubMed ID: 31263507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Traditional Japanese Herbal Medicine Yokukansan Targets Distinct but Overlapping Mechanisms in Aged Mice and in the 5xFAD Mouse Model of Alzheimer's Disease.
    Kaushik R; Morkovin E; Schneeberg J; Confettura AD; Kreutz MR; Senkov O; Dityatev A
    Front Aging Neurosci; 2018; 10():411. PubMed ID: 30631278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex.
    Egashira N; Iwasaki K; Ishibashi A; Hayakawa K; Okuno R; Abe M; Uchida N; Mishima K; Takasaki K; Nishimura R; Oishi R; Fujiwara M
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1516-20. PubMed ID: 18558456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease.
    Furukawa K; Tomita N; Uematsu D; Okahara K; Shimada H; Ikeda M; Matsui T; Kozaki K; Fujii M; Ogawa T; Umegaki H; Urakami K; Nomura H; Kobayashi N; Nakanishi A; Washimi Y; Yonezawa H; Takahashi S; Kubota M; Wakutani Y; Ito D; Sasaki T; Matsubara E; Une K; Ishiki A; Yahagi Y; Shoji M; Sato H; Terayama Y; Kuzuya M; Araki N; Kodama M; Yamaguchi T; Arai H
    Geriatr Gerontol Int; 2017 Feb; 17(2):211-218. PubMed ID: 26711658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro identification of human cytochrome P450 isoforms involved in the metabolism of Geissoschizine methyl ether, an active component of the traditional Japanese medicine Yokukansan.
    Matsumoto T; Kushida H; Maruyama T; Nishimura H; Watanabe J; Maemura K; Kase Y
    Xenobiotica; 2016; 46(4):325-34. PubMed ID: 26337900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily administration of yokukansan and keishito prevents social isolation-induced behavioral abnormalities and down-regulation of phosphorylation of neuroplasticity-related signaling molecules in mice.
    Fujiwara H; Han Y; Ebihara K; Awale S; Araki R; Yabe T; Matsumoto K
    BMC Complement Altern Med; 2017 Apr; 17(1):195. PubMed ID: 28376888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.